Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

343 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Clinical features of hypersensitivity reactions to oxaliplatin: a 10-year experience.
Polyzos A, Tsavaris N, Gogas H, Souglakos J, Vambakas L, Vardakas N, Polyzos K, Tsigris C, Mantas D, Papachristodoulou A, Nikiteas N, Karavokyros JG, Felekouras E, Griniatsos J, Giannopoulos A, Kouraklis G. Polyzos A, et al. Among authors: gogas h. Oncology. 2009;76(1):36-41. doi: 10.1159/000178163. Epub 2008 Nov 26. Oncology. 2009. PMID: 19033714
A plain language summary of the 7-year update from part 1 of the COLUMBUS study: encorafenib and binimetinib for people with BRAF V600-mutant melanoma.
Schadendorf D, Dummer R, Flaherty KT, Robert C, Arance A, de Groot JWB, Garbe C, Gogas HJ, Gutzmer R, Krajsová I, Liszkay L, Loquai C, Mandalà M, Yamazaki N, Queirolo P, Guenzel C, Polli A, Thakur M, di Pietro A, Ascierto PA. Schadendorf D, et al. Among authors: gogas hj. Future Oncol. 2025 Jan 14:1-12. doi: 10.1080/14796694.2024.2442851. Online ahead of print. Future Oncol. 2025. PMID: 39810544
Three-Year Overall Survival With Nivolumab Plus Relatlimab in Advanced Melanoma From RELATIVITY-047.
Tawbi HA, Hodi FS, Lipson EJ, Schadendorf D, Ascierto PA, Matamala L, Castillo Gutiérrez E, Rutkowski P, Gogas H, Lao CD, Janoski De Menezes J, Dalle S, Arance AM, Grob JJ, Ratto B, Rodriguez S, Mazzei A, Dolfi S, Long GV. Tawbi HA, et al. Among authors: gogas h. J Clin Oncol. 2024 Dec 13:JCO2401124. doi: 10.1200/JCO.24.01124. Online ahead of print. J Clin Oncol. 2024. PMID: 39671533
Cutaneous melanoma: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up.
Amaral T, Ottaviano M, Arance A, Blank C, Chiarion-Sileni V, Donia M, Dummer R, Garbe C, Gershenwald JE, Gogas H, Guckenberger M, Haanen J, Hamid O, Hauschild A, Höller C, Lebbé C, Lee RJ, Long GV, Lorigan P, Muñoz Couselo E, Nathan P, Robert C, Romano E, Schadendorf D, Sondak V, Suijkerbuijk KPM, van Akkooi ACJ, Michelin O, Ascierto PA; ESMO Guidelines Committee. Electronic address: [email protected]. Amaral T, et al. Among authors: gogas h. Ann Oncol. 2025 Jan;36(1):10-30. doi: 10.1016/j.annonc.2024.11.006. Epub 2024 Nov 14. Ann Oncol. 2025. PMID: 39550033 No abstract available.
Molecular Alterations in Paired Epithelial Ovarian Tumors in Patients Treated with Neoadjuvant Chemotherapy.
Nikolaidi A, Papadopoulou E, Haidopoulos D, Liontos M, Fountzilas E, Tsaousis G, Goula K, Tsolaki E, Christopoulou A, Binas I, Stamatopoulou S, Koumarianou A, Karageorgopoulou S, Goussia A, Psyrri A, Papadimitriou C, Gogas H. Nikolaidi A, et al. Among authors: gogas h. Cancers (Basel). 2024 Oct 24;16(21):3580. doi: 10.3390/cancers16213580. Cancers (Basel). 2024. PMID: 39518021 Free PMC article.
Adjuvant Use of Pembrolizumab for Stage III Melanoma in a Real-World Setting in Europe.
Weichenthal M, Mangana J, Gavrilova I, Lugowska I, Shalamanova GK, Kandolf L, Chiarion-Sileni V, Mohr P, Karanikolova TS, Teterycz P, Espinosa E, Schnecko P, Cheng P, Bender M, Jiang S, Burke T, Ascierto PA, Gogas H, Rodas IM, Rutkowski P, Schadendorf D, Dummer R, For The EUMelaReg Consortium. Weichenthal M, et al. Among authors: gogas h. Cancers (Basel). 2024 Oct 22;16(21):3558. doi: 10.3390/cancers16213558. Cancers (Basel). 2024. PMID: 39517999 Free PMC article.
Immunotherapy after progression to double immunotherapy: pembrolizumab and lenvatinib versus conventional chemotherapy for patients with metastatic melanoma after failure of PD-1/CTLA-4 inhibition.
Lyrarakis G, Liontos M, Anastasopoulou A, Bouros S, Gkoufa A, Diamantopoulos P, Gogas H, Ziogas DC. Lyrarakis G, et al. Among authors: gogas h. Front Oncol. 2024 Oct 7;14:1420879. doi: 10.3389/fonc.2024.1420879. eCollection 2024. Front Oncol. 2024. PMID: 39435288 Free PMC article.
Deep Learning for Image Analysis in the Diagnosis and Management of Esophageal Cancer.
Theocharopoulos C, Davakis S, Ziogas DC, Theocharopoulos A, Foteinou D, Mylonakis A, Katsaros I, Gogas H, Charalabopoulos A. Theocharopoulos C, et al. Among authors: gogas h. Cancers (Basel). 2024 Sep 26;16(19):3285. doi: 10.3390/cancers16193285. Cancers (Basel). 2024. PMID: 39409906 Free PMC article. Review.
343 results